Please ensure Javascript is enabled for purposes of website accessibility

The Probable Reason Behind Vertex Pharmaceuticals 5% Jump in February

By Brian Feroldi - Mar 6, 2017 at 8:09AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares picked up steam during the month. Was this the simple reason behind the rally?

What happened

According to data from S&P Global Market Intelligence, shares of Vertex Pharmaceuticals (VRTX 3.19%), a large-cap biotech focused on rare diseases, rose by 5% in February. 

So what

It was a quiet month for Vertex. The company didn't issue a single press release or attend an investor conference during the month that could help to justify the move. There weren't any analyst upgrades during the period, either.

Businessman with hands in from of lips indicating secrecy/quiet.

Image source: Getty Images.

So why did shares rally? The likely reason is that the company simply benefited from the general rally in the biotechnology sector. The iShares Nasdaq Biotechnology ETF (IBB 1.72%) -- an ETF that owns a number of large-cap biotechnology stocks -- gained 6% during the month. That move closely matches Vertex's rise.

VRTX Chart

VRTX data by YCharts.

It is also worth pointing out that Vertex's stock jumped by a strong 17% in January. That hints that the stock could have caught the attention of traders who buy based on momentum, which could have also contributed to the gains.

Now what

2017 promises to be a transformative year for Vertex. Using the midpoint of its guidance range, management expects the company to grow its top-line by more than 13%. Better yet, non-GAAP spending on R&D and SG&A are only expected to grow by 5%. If the company can hit those figures then it should be able to produce a nice profit for the full year. 

Beyond the financials, investors can also look forward to a number of clinical updates. The company is expecting Phase 3 data from its tezacaftor/ivacafrot product candidate in the first half of this year. Phase 2 data readouts are also expected from VX-440 and VX-152. Both of these drugs promise to be next-generation drugs for treating Cystic Fibrosis and both already have fast-track designation from the FDA.

With profits on the way and an advancing pipeline, Vertex is providing investors with plenty of reasons for investors to feel bullish about the year ahead. While the company's shares are richly priced, this might be a high-growth biotech stock that is worth paying a premium to own.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$292.55 (3.19%) $9.05
iShares Trust - iShares Nasdaq Biotechnology ETF Stock Quote
iShares Trust - iShares Nasdaq Biotechnology ETF
$120.04 (1.72%) $2.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.